Additional prospective studies are required to validate the clinical use of GDF-15 in quantifying the relationship between obesity, heart failure, and subclinical atherosclerosis, as well as to assess its significance in individualized risk estimation and disease prevention. Here, GDF15 is linked to heart failure.